Prescription medicine
Sugammadex Brand names: Bridion
Sugammadex (Bridion) is a prescription medicine with an FDA approval on record since 2015. FDA's NDC Directory lists it from 22 generic labelers.
- Generic listed
Check it at the source: the sugammadex FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the NDA 22225 record on Drugs@FDA; every sugammadex label on DailyMed.
Highlights of the record
FDA label of March 13, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageBRIDION ® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
Forms and strengths
- 100 mg/ml
- 200 mg/2ml
- 500 mg/5ml
Injection (solution); solution; injection.
On the market
- Earliest approval on file
- December 15, 2015 Bridion, Msd Sub Merck; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 19 first June 9, 2023; 19 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 24 of which 22 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- July 27, 2026 Bridion injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,095 through July 30, 2026
What is sugammadex used for?
From the label: indications and usageBRIDION ® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
Source: FDA drug label (BRIDION), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 5171d883-fe8f-482c-97ab-40b00975b64a), via openFDA; the full label on DailyMed
Is there a generic for sugammadex (Bridion)?
The FDA approved the first generic sugammadex on June 9, 2023. 19 generic applications are approved; 19 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists sugammadex from 22 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Bridion injection: the compound patent runs to January 27, 2026 (pediatric exclusivity to July 27, 2026). A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2023 first generic approved
- 2026 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the sugammadex label say about other medicines?
The sugammadex label names 9 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Atropine | warnings and precautions | Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. |
| Dabigatran | warnings and precautions | In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses … |
| Heparin | warnings and precautions | In patients undergoing major orthopedic surgery of the lower extremity who were concomitantly treated with heparin or low molecular weight heparin for thromboprophylaxis, increases in aPTT and PT(INR) of 5.5% and 3.0%, respectively, were observed in the hour following BRIDION 4 mg/kg administration. |
| Progesterone | drug interactions | Interference with Laboratory Tests BRIDION may interfere with the serum progesterone assay. |
| Rivaroxaban | warnings and precautions | In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses … |
| Rocuronium | drug interactions | Affecting the Efficacy of BRIDION Toremifene For toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with BRIDION could occur. |
| Succinylcholine | warnings and precautions | Rocuronium or Vecuronium Do not use BRIDION to reverse blockade induced by nonsteroidal neuromuscular blocking agents such as succinylcholine or benzylisoquinolinium compounds. |
| Toremifene | drug interactions | DRUG INTERACTIONS Toremifene: Concomitant use can delay recovery. ( 7.2 ) Hormonal contraceptives: |
| Vecuronium | drug interactions | Affecting the Efficacy of BRIDION Toremifene For toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with BRIDION could occur. |
Source: FDA drug label (BRIDION), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 5171d883-fe8f-482c-97ab-40b00975b64a), via openFDA; the full label on DailyMed
What do FAERS reports show for sugammadex?
The FDA Adverse Event Reporting System holds 3,095 reports that list sugammadex among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 124 are coded as a death and 1,048 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Sugammadex side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other